Xaluritamig STEAP1 BiTE mCRPC — PatSnap Eureka
Xaluritamig STEAP1 BiTE in Post-Taxane mCRPC: Amgen Phase I/II & Lu-PSMA Landscape
Metastatic castration-resistant prostate cancer remains a disease of significant unmet need in the post-taxane setting, where durable responses are rare and sequencing of agents is complex. Explore the mechanistic basis of STEAP1-directed T-cell engagement and the competitive context against Lu-PSMA radioligand therapy.
Unmet Need in Post-Taxane mCRPC
Metastatic castration-resistant prostate cancer (mCRPC) remains a disease of significant unmet need in the post-taxane setting, where durable responses are rare and sequencing of agents is complex. Heavily pre-treated patients who have progressed through docetaxel or cabazitaxel represent a population with limited therapeutic options and poor prognosis.
Xaluritamig, Amgen's bispecific T-cell engager (BiTE) targeting STEAP1, represents a novel immunotherapeutic approach being evaluated in this heavily pre-treated population. STEAP1 — Six-Transmembrane Epithelial Antigen of the Prostate 1 — is a cell-surface antigen overexpressed in prostate cancer, making it a rational target for immunotherapeutic engagement.
According to ClinicalTrials.gov, analysts seeking primary data on xaluritamig (AMG 509) should query NCT identifiers associated with the compound, alongside ASCO and ESMO abstract archives for Phase I dose-escalation readouts. The emerging competitive pressure from lutetium-177-PSMA-617 (Lu-PSMA) radioligand therapy adds strategic complexity to Amgen's development programme.
For patent intelligence, the recommended approach is to search WIPO PatentScope, USPTO, and EPO Espacenet using Amgen Inc. as assignee with IPC classes A61K39/00 (antibody therapeutics) and C07K16/28 (bispecific antibodies). PatSnap Eureka's IP analytics platform can surface these filings with AI-powered landscape mapping.
STEAP1-Directed T-Cell Engagement vs. PSMA Radioligand
Two mechanistically distinct approaches compete in the post-taxane mCRPC space, each with a different tumour antigen target and mode of tumour cell killing.
STEAP1 BiTE: Redirecting Cytotoxic T Cells to Prostate Tumour Cells
Bispecific T-cell engager (BiTE) molecules simultaneously bind a tumour-associated antigen on cancer cells and CD3 on T cells, redirecting cytotoxic T-cell activity against tumour targets. Xaluritamig targets STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1), a cell-surface antigen overexpressed in prostate cancer. This immunotherapeutic mechanism is mechanistically distinct from radioligand therapy and represents a novel approach for heavily pre-treated mCRPC patients.
Phase I/II · Post-Taxane mCRPCPSMA Radioligand: Targeted Radiotherapy via Lutetium-177 Conjugate
Lutetium-177-PSMA-617 is a PSMA-targeted radioligand therapy that delivers localised radiation to PSMA-expressing prostate cancer cells. Competitive intelligence on Lu-PSMA-617 can be found through EMA and FDA submissions, as well as pipeline disclosures from Novartis, Lantheus, and Point Biopharma for radioligand context. The mechanism differs fundamentally from BiTE immunotherapy, creating potential for sequencing or combination strategies.
Approved (FDA/EMA) · NovartisIPC Classes A61K39/00 & C07K16/28: Bispecific Antibody Filing Strategy
For analysts seeking patent coverage of xaluritamig and related STEAP1 BiTE molecules, the recommended approach is to search USPTO, EPO (Espacenet), and WIPO PatentScope with Amgen Inc. as assignee. IPC class A61K39/00 covers antibody therapeutics broadly, while C07K16/28 is specific to bispecific antibodies. PatSnap Eureka's patent analytics tools can automate this landscape across all three offices simultaneously.
USPTO · EPO · WIPO PatentScopePubMed, ClinicalTrials.gov & ASCO/ESMO: Primary Data Pathways
For STEAP1 expression studies, PubMed/MEDLINE is the recommended primary literature source. ClinicalTrials.gov holds NCT identifiers associated with xaluritamig (AMG 509), and ASCO/ESMO abstract archives contain Phase I dose-escalation readouts. These sources collectively provide the clinical and biological evidence base that a comprehensive mCRPC competitive landscape requires, and can be systematically monitored through PatSnap's life sciences intelligence tools.
PubMed · ClinicalTrials.gov · ASCO/ESMOmCRPC Competitive Landscape: Key Dimensions for Analysis
Visualising the recommended research pathways and mechanistic comparison points identified in the source methodology for xaluritamig vs. Lu-PSMA-617.
Recommended Research Databases for Xaluritamig & STEAP1 Intelligence
Five primary source categories recommended for comprehensive mCRPC BiTE landscape analysis, weighted by data type coverage.
Mechanistic Attribute Comparison: Xaluritamig vs. Lu-PSMA-617 in mCRPC
Comparative profile across five key mechanistic and strategic dimensions for the two leading post-taxane mCRPC modalities.
Key Players in Post-Taxane mCRPC: BiTE and Radioligand Landscape
The source methodology identifies these organisations as the primary competitive actors and intelligence sources for the mCRPC treatment landscape.
Amgen — Xaluritamig (AMG 509) Sponsor
Amgen is the developer and sponsor of xaluritamig, a STEAP1-directed BiTE molecule in Phase I/II evaluation for post-taxane mCRPC. Patent filings should be searched under Amgen Inc. as assignee across USPTO, EPO, and WIPO PatentScope using IPC classes A61K39/00 and C07K16/28. The PatSnap customer success team can assist with assignee-specific landscape reports.
Novartis — Lu-PSMA-617 (Pluvicto) Market Leader
Novartis holds the approved radioligand therapy for post-taxane mCRPC with lutetium-177-PSMA-617 (vipivotide tetraxetan / Pluvicto). EMA and FDA submissions for 177Lu-PSMA-617 provide the regulatory intelligence baseline for competitive analysis. Novartis's pipeline disclosures are a key source for understanding the evolving radioligand therapy landscape against which Amgen's xaluritamig is competing.
Where to Find Primary Data on Xaluritamig, STEAP1, and mCRPC Competitors
| Source / Database | Data Type | Recommended Query | Relevance to Xaluritamig / mCRPC |
|---|---|---|---|
| USPTO | Patent | Amgen Inc. assignee + IPC A61K39/00 | Bispecific antibody therapeutic filings including STEAP1-directed BiTE molecules |
| EPO Espacenet | Patent | Amgen Inc. assignee + IPC C07K16/28 | European bispecific antibody filings; cross-reference with WIPO for PCT coverage |
| WIPO PatentScope | Patent | PCT applications, Amgen assignee | International patent applications covering xaluritamig and related STEAP1 BiTE molecules |
| PubMed / MEDLINE | Literature | STEAP1 expression studies; mCRPC immunotherapy | Primary biological evidence for STEAP1 as a prostate cancer target antigen |
| ClinicalTrials.gov | Clinical | NCT identifiers for xaluritamig (AMG 509) | Phase I/II dose-escalation design, endpoints, eligibility criteria for post-taxane mCRPC |
| ASCO / ESMO Archives | Clinical | Phase I dose-escalation readouts; mCRPC abstracts | Early efficacy and safety signals from xaluritamig Phase I programme |
| EMA / FDA Submissions | Regulatory | 177Lu-PSMA-617 (vipivotide tetraxetan) | Approved competitor data: efficacy, safety, label — competitive benchmark for xaluritamig |
Search All These Sources in One Platform
PatSnap Eureka aggregates patent, literature, and clinical data — no database-hopping required.
Xaluritamig STEAP1 BiTE in mCRPC — key questions answered
Xaluritamig (AMG 509) is Amgen's bispecific T-cell engager (BiTE) targeting STEAP1 (Six-Transmembrane Epithelial Antigen of the Prostate 1). BiTE molecules simultaneously bind a tumour-associated antigen on cancer cells and CD3 on T cells, redirecting cytotoxic T-cell activity against tumour targets. STEAP1 is a cell-surface antigen overexpressed in prostate cancer, making it a rational target for immunotherapeutic engagement in metastatic castration-resistant prostate cancer (mCRPC).
Xaluritamig is being evaluated in Phase I/II clinical trials in the post-taxane mCRPC setting. Analysts seeking primary data should consult ClinicalTrials.gov for NCT identifiers associated with xaluritamig (AMG 509) and ASCO/ESMO abstract archives for Phase I dose-escalation readouts.
Xaluritamig and lutetium-177-PSMA-617 (Lu-PSMA) represent mechanistically distinct approaches. Xaluritamig is a STEAP1-directed immunotherapy engaging T cells, while Lu-PSMA-617 is a PSMA-targeted radioligand therapy. Both compete in the post-taxane mCRPC space. Competitive intelligence on Lu-PSMA-617 can be found through EMA and FDA submissions, as well as pipeline disclosures from Novartis, Lantheus, and Point Biopharma.
Patent databases to query directly include USPTO, EPO (Espacenet), and WIPO PatentScope. Search Amgen Inc. as assignee with IPC classes A61K39/00 (antibody therapeutics) and C07K16/28 (bispecific antibodies) to locate relevant filings covering STEAP1-directed BiTE molecules and related prostate cancer immunotherapy patents.
Metastatic castration-resistant prostate cancer (mCRPC) remains a disease of significant unmet need in the post-taxane setting, where durable responses are rare and sequencing of agents is complex. Heavily pre-treated patients have limited options, driving interest in novel mechanisms such as STEAP1-directed T-cell engagement and radioligand therapy.
Key players in the PSMA-directed radioligand therapy space include Novartis (lutetium-177-PSMA-617 / Pluvicto), Lantheus, and Point Biopharma. EMA and FDA submissions for 177Lu-PSMA-617, along with pipeline disclosures from these companies, provide competitive context for the post-taxane mCRPC landscape alongside Amgen's xaluritamig programme.
Still have questions? Let PatSnap Eureka search the patent and clinical literature for you.
Ask PatSnap Eureka About xaluritamig →Accelerate Your mCRPC & STEAP1 BiTE Research with AI-Powered Intelligence
Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D — search patents, literature, and clinical data in one platform.
References
- ClinicalTrials.gov — NCT identifiers for xaluritamig (AMG 509) Phase I/II in mCRPC
- WIPO PatentScope — PCT applications, Amgen Inc. assignee, IPC A61K39/00 and C07K16/28
- EMA — Regulatory submissions for lutetium-177-PSMA-617 (vipivotide tetraxetan / Pluvicto)
- PubMed/MEDLINE — STEAP1 expression studies in prostate cancer and mCRPC immunotherapy literature
- FDA — Submissions and approvals for 177Lu-PSMA-617 in post-taxane mCRPC
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. Note: The underlying dataset for this topic returned zero retrievable patent or literature records under the strict methodology governing this report. Research pathways are derived directly from the source content's recommended next steps.
PatSnap Eureka searches patents and research to answer instantly.